These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16120179)

  • 1. Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo?
    Legros L; Cassuto JP; Ortonne JP
    Br J Dermatol; 2005 Sep; 153(3):691-2. PubMed ID: 16120179
    [No Abstract]   [Full Text] [Related]  

  • 2. Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate.
    Anthony N; Shanks J; Terebelo H
    Leuk Res; 2010 Sep; 34(9):1250-1. PubMed ID: 20646761
    [No Abstract]   [Full Text] [Related]  

  • 3. Antituberculosis therapy and imatinib for chronic myeloid leukemia.
    Sorà F; De Matteis S; Di Mario A; Maiuro G; Laurenti L; Chiusolo P; Ardito F; Leone G; Sica S
    Clin Infect Dis; 2006 Nov; 43(9):1224. PubMed ID: 17029152
    [No Abstract]   [Full Text] [Related]  

  • 4. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia.
    Mariani S; Tornaghi L; Sassone M; Basciani S; Buzzetti R; Gambacorti-Passerini C; Spera G; Gnessi L
    Leuk Res; 2010 Jan; 34(1):e5-7. PubMed ID: 19717189
    [No Abstract]   [Full Text] [Related]  

  • 6. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
    Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
    Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
    Mcpherson T; Sherman V; Turner R
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
    Uchiyama M; Ikeda T
    Leuk Res; 2009 Dec; 33(12):1723-4. PubMed ID: 19580999
    [No Abstract]   [Full Text] [Related]  

  • 9. Persistence of molecular remission throughout pregnancy in CML after imatinib.
    Sorà F; De Matteis S; Bajer J; D'alò F; Leone G; Sica S
    Leuk Res; 2009 Jun; 33(6):e6-7. PubMed ID: 18937976
    [No Abstract]   [Full Text] [Related]  

  • 10. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
    Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
    Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
    Jin J; Chen H; Cao L
    Leuk Res; 2009 Jun; 33(6):e18-9. PubMed ID: 19108890
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
    Richardson MW; Grewal SS
    Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
    [No Abstract]   [Full Text] [Related]  

  • 14. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib mesylate and gray hair.
    Etienne G; Cony-Makhoul P; Mahon FX
    N Engl J Med; 2002 Aug; 347(6):446. PubMed ID: 12167692
    [No Abstract]   [Full Text] [Related]  

  • 16. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
    Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
    [No Abstract]   [Full Text] [Related]  

  • 17. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients.
    Brazzelli V; Prestinari F; Barbagallo T; Rona C; Orlandi E; Passamonti F; Locatelli F; Zecca M; Villani S; Borroni G
    J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):384-7. PubMed ID: 17309464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the use of imatinib mesylate.
    Sawyers CL
    Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
    Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Messina A; Di Raimondo F
    Leuk Res; 2009 Jun; 33(6):e17. PubMed ID: 19036439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.